These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 27266878)

  • 21. Drugs for rare diseases: mixed assessment in Europe.
    Prescrire Int; 2007 Feb; 16(87):36-42. PubMed ID: 17323539
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Medical expenditure and rural impoverishment in China.
    Liu Y; Rao K; Hsiao WC
    J Health Popul Nutr; 2003 Sep; 21(3):216-22. PubMed ID: 14717567
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Estimating the clinical cost of drug development for orphan versus non-orphan drugs.
    Jayasundara K; Hollis A; Krahn M; Mamdani M; Hoch JS; Grootendorst P
    Orphanet J Rare Dis; 2019 Jan; 14(1):12. PubMed ID: 30630499
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patient Access to Orphan Drugs Covered by Medical Insurance in China: Real-World Evidence From Patient Survey.
    Wang X; Li SC; Yue X; Li Y; Shi N; Zhao FL; Wu J
    Value Health Reg Issues; 2023 Mar; 34():71-77. PubMed ID: 36587572
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reducing out-of-pocket expenditures to reduce poverty: a disaggregated analysis at rural-urban and state level in India.
    Garg CC; Karan AK
    Health Policy Plan; 2009 Mar; 24(2):116-28. PubMed ID: 19095685
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Factors that determine catastrophic expenditure for tuberculosis care: a patient survey in China.
    Zhou C; Long Q; Chen J; Xiang L; Li Q; Tang S; Huang F; Sun Q; Lucas H
    Infect Dis Poverty; 2016 Jan; 5():6. PubMed ID: 26806552
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drugs for rare diseases: influence of orphan designation status on price.
    Picavet E; Dooms M; Cassiman D; Simoens S
    Appl Health Econ Health Policy; 2011 Jul; 9(4):275-9. PubMed ID: 21682354
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Financial burden of household out-of pocket health expenditure in Viet Nam: findings from the National Living Standard Survey 2002-2010.
    Van Minh H; Kim Phuong NT; Saksena P; James CD; Xu K
    Soc Sci Med; 2013 Nov; 96():258-63. PubMed ID: 23246399
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Catastrophic healthcare expenditure - drivers and protection: the Portuguese case.
    Kronenberg C; Barros PP
    Health Policy; 2014 Mar; 115(1):44-51. PubMed ID: 24210762
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Budgetary Impact and Cost Drivers of Drugs for Rare and Ultrarare Diseases.
    Schlander M; Dintsios CM; Gandjour A
    Value Health; 2018 May; 21(5):525-531. PubMed ID: 29753348
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A discrete choice experiment investigating preferences for funding drugs used to treat orphan diseases: an exploratory study.
    Mentzakis E; Stefanowska P; Hurley J
    Health Econ Policy Law; 2011 Jul; 6(3):405-33. PubMed ID: 21205401
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Limits on use of health economic assessments for rare diseases.
    Hyry HI; Stern AD; Cox TM; Roos JC
    QJM; 2014 Mar; 107(3):241-5. PubMed ID: 24453281
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Financial access to health care for older people in Cambodia: 10-year trends (2004-14) and determinants of catastrophic health expenses.
    Jacobs B; de Groot R; Fernandes Antunes A
    Int J Equity Health; 2016 Jun; 15():94. PubMed ID: 27316716
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New cooperative medical scheme decreased financial burden but expanded the gap of income-related inequity: evidence from three provinces in rural China.
    Ma J; Xu J; Zhang Z; Wang J
    Int J Equity Health; 2016 May; 15():72. PubMed ID: 27142618
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Catastrophic payment for assisted reproduction techniques with conventional ovarian stimulation in the public health sector of South Africa: frequency and coping strategies.
    Dyer SJ; Sherwood K; McIntyre D; Ataguba JE
    Hum Reprod; 2013 Oct; 28(10):2755-64. PubMed ID: 23878180
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of orphan drugs on Latvian budget.
    Logviss K; Krievins D; Purvina S
    Orphanet J Rare Dis; 2016 May; 11(1):59. PubMed ID: 27169704
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluating and Valuing Drugs for Rare Conditions: No Easy Answers.
    Ollendorf DA; Chapman RH; Pearson SD
    Value Health; 2018 May; 21(5):547-552. PubMed ID: 29753351
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Economic considerations in the provision of treatments for rare diseases.
    McCabe C; Edlin R; Round J
    Adv Exp Med Biol; 2010; 686():211-22. PubMed ID: 20824448
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Patient Access to Medicines for Rare Diseases in European Countries.
    Detiček A; Locatelli I; Kos M
    Value Health; 2018 May; 21(5):553-560. PubMed ID: 29753352
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Orphan drugs: availability, reliability and reimbursement].
    Kreeftmeijer-Vegter AR; van Veldhuizen CK; de Vries PJ
    Ned Tijdschr Geneeskd; 2012; 156(17):A4252. PubMed ID: 22531041
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.